Market Overview

UPDATE: Benchmark Downgrades ICU Medical to Hold on Valuation

Share:

In a report published Thursday, Benchmark Company analyst James Terwilliger downgraded the rating on ICU Medical (NASDAQ: ICUI) from Buy to Hold, but reiterated the $69.00 price target.

In the report, Terwilliger noted, “We are lowering our recommendation to Hold from Buy based on valuation as ICU Medical has traded close to our $69.00 price target. Our $69.00 price target represents 20 times our 2013 EPS estimate of $2.80 plus $13.00 in cash per share. We remind investors that ICU Medical has a strong balance sheet with approximately $16.00 in cash per share and no long-term debt. We believe that ICU Medical could be exploring a sale of the company, according to a Bloomberg News report.”

ICU Medical closed on Wednesday at $68.80.

Latest Ratings for ICUI

DateFirmActionFromTo
Aug 2019DowngradesStrong BuyOutperform
Mar 2019MaintainsStrong BuyStrong Buy
Oct 2017Initiates Coverage OnSector Weight

View More Analyst Ratings for ICUI
View the Latest Analyst Ratings

Posted-In: Benchmark CompanyAnalyst Color Downgrades Analyst Ratings

 

Related Articles (ICUI)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
WEEDCantor FitzgeraldMaintains18.9
TGTXCantor FitzgeraldMaintains19.0
SPLKCleveland ResearchDowngrades
IQVWolfe ResearchUpgrades
PRAHWolfe ResearchUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: Bank of America Upgrades Ctrip.com International to Buy Following Strong 1Q13 Results

UPDATE: Piper Jaffray Downgrades Hansen Medical to Neutral on Continued Sales Uncertainty